<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">CNS Neurosci Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">CNS Neurosci Ther</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1755-5949</journal-id>
<journal-id journal-id-type="publisher-id">CNS</journal-id>
<journal-title-group>
<journal-title>CNS Neuroscience &amp; Therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1755-5930</issn>
<issn pub-type="epub">1755-5949</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26842941</article-id>
<article-id pub-id-type="pmc">5067581</article-id>
<article-id pub-id-type="doi">10.1111/cns.12506</article-id>
<article-id pub-id-type="publisher-id">CNS12506</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation <italic>In Vitro</italic> and Neuroprotection During the Cuprizone‐Induced Central Nervous System Demyelination</article-title>
<alt-title alt-title-type="left-running-head">J. Tomas‐Roig <italic>et al</italic>.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" id="cns12506-cr-0001">
<name>
<surname>Tomas‐Roig</surname>
<given-names>Jordi</given-names>
</name>
<xref ref-type="aff" rid="cns12506-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cns12506-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="cns12506-note-0001">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cns12506-cr-0002">
<name>
<surname>Wirths</surname>
<given-names>Oliver</given-names>
</name>
<xref ref-type="aff" rid="cns12506-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cns12506-cr-0003">
<name>
<surname>Salinas‐Riester</surname>
<given-names>Gabriela</given-names>
</name>
<xref ref-type="aff" rid="cns12506-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="cns12506-cr-0004">
<name>
<surname>Havemann‐Reinecke</surname>
<given-names>Ursula</given-names>
</name>
<xref ref-type="aff" rid="cns12506-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="cns12506-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="cns12506-note-0001">
<sup>†</sup>
</xref>
</contrib>
</contrib-group>
<aff id="cns12506-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Psychiatry and Psychotherapy</named-content>
<institution>University Medical Center Göttingen</institution>
<named-content content-type="city">Göttingen</named-content>
<country country="DE">Germany</country>
</aff>
<aff id="cns12506-aff-0002">
<label><sup>2</sup></label>
<institution>Center Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB)</institution>
<named-content content-type="city">Göttingen</named-content>
<country country="DE">Germany</country>
</aff>
<aff id="cns12506-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Division of Molecular Psychiatry</named-content>
<named-content content-type="organisation-division">Department of Psychiatry and Psychotherapy</named-content>
<institution>University Medical Center Göttingen</institution>
<named-content content-type="city">Göttingen</named-content>
<country country="DE">Germany</country>
</aff>
<aff id="cns12506-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Developmental Biochemistry</named-content>
<institution>University Medical Center Göttingen</institution>
<named-content content-type="city">Göttingen</named-content>
<country country="DE">Germany</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Dr. J. Tomas‐Roig, Department of Psychiatry and Psychotherapy, Georg‐August‐Universität Göttingen, Von‐Siebold‐Str. 5, Göttingen 37075, Germany.<break></break>
Tel.: +49‐551‐396141;<break></break>
Fax: +49‐551‐3922241;<break></break>
E‐mail: <email>jordi.tomas-roig@med.uni-goettingen</email><break></break></corresp>
<fn id="cns12506-note-0001">
<label>†</label>
<p>These authors share senior authorship.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2016</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<issue-id pub-id-type="doi">10.1111/cns.2016.22.issue-5</issue-id>
<fpage>387</fpage>
<lpage>395</lpage>
<history>
<date date-type="received">
<day>12</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>07</day>
<month>12</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>12</month>
<year>2015</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2016 John Wiley & Sons Ltd <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2016 The Authors. <italic>CNS Neuroscience &amp; Therapeutics</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
<license license-type="creativeCommonsBy-nc-nd">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:CNS-22-387.pdf" xlink:type="simple"></self-uri>
<abstract id="cns12506-abs-0001">
<title>Summary</title>
<sec id="cns12506-sec-0001">
<title>Aim and methods</title>
<p>Different types of insults to the CNS lead to axon demyelination. Remyelination occurs when the CNS attempts to recover from myelin loss and requires the activation of oligodendrocyte precursor cells. With the rationale that CB1 receptor is expressed in oligodendrocytes and marijuana consumption alters CNS myelination, we study the effects of the cannabinoid agonist WIN55212.2 in (1) an <italic>in vitro</italic> model of oligodendrocyte differentiation and (2) the cuprizone model for demyelination.</p>
</sec>
<sec id="cns12506-sec-0002">
<title>Results</title>
<p>The synthetic cannabinoid agonist WIN55212.2 at 1 <italic>μ</italic>M increased the myelin basic protein mRNA and protein expression <italic>in vitro</italic>. During cuprizone‐induced acute demyelination, the administration of 0.5 mg/kg WIN55212.2 confers more myelinated axons, increased the expression of retinoid X receptor alpha, and declined nogo receptor expression. Controversially, 1 mg/kg of the drug increased the number of demyelinated axons and reduced the expression of nerve growth factor inducible, calreticulin and myelin‐related genes coupling specifically with a decrease in 2′,3′‐cyclic nucleotide 3′ phosphodiesterase expression.</p>
</sec>
<sec id="cns12506-sec-0003">
<title>Conclusion</title>
<p>The cannabinoid agonist WIN55212.2 promotes oligodendrocyte differentiation <italic>in vitro</italic>. Moreover, 0.5 mg/kg of the drug confers neuroprotection during cuprizone‐induced demyelination, while 1 mg/kg aggravates the demyelination process.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="cns12506-kwd-0001">Cuprizone</kwd>
<kwd id="cns12506-kwd-0002">Demyelination</kwd>
<kwd id="cns12506-kwd-0003">Endocannabinoid system</kwd>
<kwd id="cns12506-kwd-0004">Neuroprotection</kwd>
<kwd id="cns12506-kwd-0005">Oligodendrocyte</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>DFG CNMPB</funding-source>
<award-id>CNMPB C1‐6</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="9"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>cns12506</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May 2016</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:02.05.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group id="cns12506-ntgp-0001">
<fn id="cns12506-note-1102">
<p>The copyright line for this article was changed on 25 March, 2016 after original online publication.</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<sec id="cns12506-sec-0004">
<title>Introduction</title>
<p>Understanding how different populations of neurons develop, integrate, and function as a whole has direct impact for the etiology of neurological disorders. Neurons represent a major cell type in the central nervous system (CNS) and are critically associated with glial cells in the formation of effective synapses which provide communication in a timely manner <xref ref-type="ref" rid="cns12506-bib-0001">1</xref>. Oligodendrocytes are a type of glial cells that wrapped axons in the CNS to produce large amounts of myelin sheath <xref ref-type="ref" rid="cns12506-bib-0001">1</xref>. Myelin sheath isolates the axon and promotes the action potentials propagation <xref ref-type="ref" rid="cns12506-bib-0002">2</xref>. Some types of injuries to the CNS drive axonal demyelination and cause severe disorders such as multiple sclerosis, neuropathies, myelopathies, and leukodystrophies. One of the most crucial steps in remyelination is the stimulation of oligodendrocyte precursor cells (OPCs), which progress across several stages from immature to mature oligodendrocytes <xref ref-type="ref" rid="cns12506-bib-0001">1</xref>. The cuprizone (CPZ) mouse model allows the investigation of the complex molecular mechanisms behind non‐autoimmune‐mediated demyelination. Matsushima and Morell <xref ref-type="ref" rid="cns12506-bib-0003">3</xref> determined that C57BL/6 mice fed with 0.2% CPZ‐supplemented diet for 4–6 weeks displayed acute demyelinating lesions followed by spontaneous remyelination.</p>
<p>By activating cannabinoid receptors, Gomez et al. <xref ref-type="ref" rid="cns12506-bib-0004">4</xref> reported a markedly oligodendrocyte differentiation <italic>in vitro</italic>. The effects of cannabinoids are classically associated with CB1 and CB2 receptors. These receptors are key components of the endocannabinoid system as well as the endogenous cannabinoids ligands, their carriers, and synthetic/degrading enzymes <xref ref-type="ref" rid="cns12506-bib-0005">5</xref>. CB1 receptor is highly expressed in the brain <xref ref-type="ref" rid="cns12506-bib-0006">6</xref> and it is essential for several behaviors including anxiety and fear responses (for review, see <xref ref-type="ref" rid="cns12506-bib-0007">7</xref>). The most important endogenous ligands for cannabinoid receptors are N‐arachidonylethanolamine (AEA) <xref ref-type="ref" rid="cns12506-bib-0008">8</xref> and 2‐arachidonoylglycerol (2‐AG) <xref ref-type="ref" rid="cns12506-bib-0009">9</xref>. N‐Arachidonoylphospatidylethanolamine phospholipase D (Napepld) is the central enzyme responsible for the synthesis of AEA, while 2‐AG is mainly produced by diacylglycerol lipase (Dagla) in the adult brain as described <xref ref-type="ref" rid="cns12506-bib-0010">10</xref>. After the activation of cannabinoid receptors, AEA and 2‐AG are removed from the synaptic cleft and hydrolyzed by the action of fatty acid amide hydrolase (Faah) and monoacylglycerol lipase (Magl), respectively <xref ref-type="ref" rid="cns12506-bib-0011">11</xref>.</p>
<p>With the rationale that CB1 receptor is expressed in oligodendrocytes <xref ref-type="ref" rid="cns12506-bib-0004">4</xref> and marijuana consumption alters CNS myelination <xref ref-type="ref" rid="cns12506-bib-0012">12</xref>, <xref ref-type="ref" rid="cns12506-bib-0013">13</xref>, we directed the present study to evaluate the effects of the cannabinoid CB1/CB2 agonist WIN55212.2 in (1) an <italic>in vitro</italic> model of oligodendrocyte differentiation and (2) the murine model of demyelination by cuprizone.</p>
</sec>
<sec id="cns12506-sec-0005">
<title>Materials and Methods</title>
<p>A total of 90 C57Bl6/J male mice at the age of 7–8 weeks were obtained from Charles River Laboratories (Germany). After arrival, the animals were housed 5 mice per cage and maintained under standard conditions (12‐h light/dark cycle with 6:00/18:00 lights on/off, room temperature of 21 ± 2°C, and food and water <italic>ad libitum</italic>). Procedures performed on mice were in accordance with NIH guidelines for the use of animals in research and the European Communities Council Directive (86/609/EEC).</p>
<sec id="cns12506-sec-0006">
<title>HOG16 Oligodendrocyte <italic>In Vitro</italic> Model</title>
<p>The cell line HOG16 was obtained from Eucellbank (University of Barcelona, Spain) in agreement with Dr. G. Dawson (University of Chicago, USA). Oligodendrocytes were cultured in standard medium containing high‐glucose Dulbecco's modified Eagle medium (Invitrogen Ltd., Warrington, UK) complemented with 10% fetal bovine serum (HyClone, Logan, UT, USA), the antibiotics penicillin (50 U/mL) and streptomycin (50 <italic>μ</italic>g/mL) (Invitrogen Ltd., UK) at fully humidified atmosphere incubator at 37°C and 5% CO<sub>2</sub>. To induce differentiation, cells were exposed to differentiation medium that contained 0.05% FBS, 30 nM triiodothyronine (T3), 30 nM selenium, 0.5 <italic>μ</italic>g/mL insulin (all from Sigma–Aldrich, Munich, Germany), 50 <italic>μ</italic>g/mL transferrin (US Biological, Salem, MA, USA), and the antibiotics used above <xref ref-type="ref" rid="cns12506-bib-0014">14</xref>. The effect of 1 <italic>μ</italic>M WIN55212.2 (WIN) (Sigma–Aldrich) was tested under both conditions according to Bologov et al., <xref ref-type="ref" rid="cns12506-bib-0015">15</xref>. Cells grew with standard medium and when they reached 50% confluency were divided into two groups. One of them remained with standard medium, and in the other one, the medium was replaced by differentiation medium. After 24 h, the cells were subjected to lysis buffer or fixed. Quantitative RT‐PCR was performed in triplicate wells and in three independent experiments. Immunohistochemistry was carried out in a Lab‐Tek II Chamber Slide System (Nunc, Roskilde, Denmark). Figure <xref ref-type="fig" rid="cns12506-fig-0001">1</xref>(A) shows a schematic drawing of the experiment.</p>
<fig fig-type="Figure" id="cns12506-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Schematic drawing of the experiment. (<bold>A</bold>) The human oligodendroglial cell line HOG16 was cultured in standard medium, and when they reached 50% confluency, cells were subjected to differentiation medium according to Bologov et al., <xref ref-type="ref" rid="cns12506-bib-0015">15</xref>. The effect of 1 <italic>μ</italic>M cannabinoid agonist WIN was tested under both conditions. (<bold>B</bold>) C57Bl6/J male mice at 8 weeks of age were divided into control groups fed with a regular diet for 0, 3, and 12 weeks (controls) or those mice that received a diet supplemented with 0.2% CPZ for 3 and 6 weeks (treated). In parallel, mice fed with CPZ were single daily injected with WIN (drug) or phosphate‐buffered saline (vehicle). After 0, 3, and 12 weeks, mice were evaluated by behavioral testing, and finally, they were sacrificed as indicated vertical arrows.</p>
</caption>
<graphic id="nlm-graphic-1" xlink:href="CNS-22-387-g001"></graphic>
</fig>
</sec>
<sec id="cns12506-sec-0007">
<title>Immunocytochemistry on Cell Culture</title>
<p>The cells were washed in phosphate‐buffered saline (PBS), fixed in 2% paraformaldehyde (PFA) for 30 min, permeabilized with 0.05% Triton X‐100 for 30 min, washed in PBS, and incubated overnight at 4°C in PBS with anti‐CB1 receptor antibody (ab23703, dilution 1:300; Abcam, Bristol, UK) and anti‐MBP antibody (250746, dilution 1:250; Abbiotec, Aachen, Germany). Next day, after washing the cells with PBS, they were incubated for 30 min with goat anti‐rabbit DyLight488‐labeled secondary antibody (46402, dilution 1:300; Thermo Scientific, Karlsruhe, Germany), and finally, the excess of secondary antibody was eluted washing with PBS <xref ref-type="ref" rid="cns12506-bib-0014">14</xref>. Cells were analyzed under a fluorescence microscope (Olympus light microscope BX51, Hamburg, Germany) equipped with a camera and filters that allow excitation at 495/10 nm, and labeled structures were digitally photographed using ×100 magnification.</p>
</sec>
<sec id="cns12506-sec-0008">
<title>The Cuprizone Murine Model</title>
<p>Mice received regular diet for 0, 3, and 12 weeks (controls) or were fed with 0.2% CPZ for 3 and 6 weeks (treated). In the recovery group, animals were fed with CPZ for 6 weeks, followed by a recovery period of 6 weeks with regular diet. In parallel to CPZ feeding, mice were intraperitoneally injected with WIN or phosphate‐buffered saline (vehicle) once per day. WIN was dissolved in 10% DMSO (Sigma–Aldrich), 0.1% Tween 80 (Sigma–Aldrich) in 0.9% saline and prepared freshly every day. The same volume of WIN (drug) or phosphate‐buffered saline (vehicle) (200 <italic>μ</italic>L) was applied i.p. The drug was administered at 0.5 or 1 mg/kg. At certain time points (at 3 and 12 weeks), mice were evaluated by testing the baseline startle response and prepulse inhibition (PPI). After behavioral testing, mice were deeply anesthetized by intraperitoneal injection of 2,2,2‐tribromoethanol (Sigma‐Aldrich, Germany) and transcardially perfused with cold PBS. From one half of the brain, the corpus callosum was dissected and collected for RNA analysis. The other half of the brain was fixed with 4% PFA and processed later for EPON embedding. We selected this brain region because it is mainly affected in this model <xref ref-type="ref" rid="cns12506-bib-0003">3</xref>. Although this approach is not ideal for the electron microscopy sample preparation, we have chosen this experimental design to be able to perform RNA and morphological analysis on same brain tissue. Figure <xref ref-type="fig" rid="cns12506-fig-0001">1</xref>(B) shows a schematic drawing of the experiment.</p>
</sec>
<sec id="cns12506-sec-0009">
<title>Startle response and Prepulse Inhibition (PPI)</title>
<p>An experimental session consisted of a 3‐min habituation to 65 dB background white noise (continuously during the session), followed by a baseline recording for 2 min. Startle reflexes were resulted from an acoustic stimuli. The startle reaction to an acoustic stimulus evoked a movement of the platform which was recorded during a frame time of 100 ms (the onset of the acoustic stimulus) and stored for further analysis. For prepulse inhibition tests, the 120‐dB startle pulse of 40‐ms duration was applied either alone or preceded by a nonstartling prepulse stimulus of 70‐, 75‐, or 80‐dB intensity and 20‐ms duration. An interval of 100 ms with background white noise was used between each prepulse and pulse stimulus. Ten trials of each type were displayed in a randomly order with intertrial intervals ranging from 8 to 22 seconds. The amplitude of the startle response (AUs) during recording frame time was determined as the maximum force displayed during a reaction to 120‐dB acoustic stimulus. Maximum amplitudes were averaged individually, separately for all types of trials as described <xref ref-type="ref" rid="cns12506-bib-0016">16</xref>.</p>
</sec>
<sec id="cns12506-sec-0010">
<title>RNA Isolation</title>
<p>The corpus callosum from each of the CPZ‐exposed and controls was sonicated with a blender in RNase‐free lysis buffer (Applied Biosystems, Carlsbad, CA, USA). Cell cultures were stopped by removing the medium and adding RNase‐free lysis buffer (Applied Biosystems, USA). Samples were kept for 1 h at 4°C. Total RNA was isolated using the TRIzol protocol (Invitrogen Ltd., Darmstadt, Germany). The RNA was digested with RNase‐free DNase (Qiagen, Valencia, CA, USA) and checked for integrity by electrophoresis (Bioanalyzer; Agilent Technologies, Santa Clara, CA, USA). N = 5 mice/group.</p>
</sec>
<sec id="cns12506-sec-0011">
<title>Electron Microscopy</title>
<p>As described above, mice were deeply anesthetized and transcardially perfused with PBS; half of the brain was dissected and immersion‐fixed in 4% PFA and stored at 4°C. Later, the brains were postfixed with 4% formaldehyde (Serva, Heidelberg, Germany), 2.5% glutaraldehyde (Science Services, Munich, Germany), and 0.5% NaCl in phosphate buffer pH 7.4 <xref ref-type="ref" rid="cns12506-bib-0017">17</xref>. Finally, the corpus callosum was postfixed with 2% OsO<sub>4</sub> (Science Services) in 0.1 M phosphate buffer pH 7.3 and embedded in EPON (Serva) after dehydration with ethanol and propylene oxide. EPON blocks with embedded tissue were then trimmed, using a Leica EM TRIM (Leica, Vienna, Austria), to the size of the corpus callosum. In the following, ultrathin sections were stained with an aqueous solution of 4% uranyl acetate followed by lead citrate <xref ref-type="ref" rid="cns12506-bib-0018">18</xref>. The pictures were taken in an unbiased random fashion with a Zeiss EM900 electron microscope (Zeiss, Oberkochen, Germany) using a side‐mounted 2k CCD camera (TRS, Waakirchen, Germany). Counting of myelinated and demyelinated axons was performed using NIH ImageJ software (National Institutes of Health, Bethesda, MD, USA); a total area of 10*784 <italic>μ</italic>m<sup>2</sup> = 7840 <italic>μ</italic>m<sup>2</sup> was analyzed per mouse and every axon counted. The g ratio was calculated as the ratio between the number of demyelinated axons and the number of myelinated axons. Counting was performed on groups of n = 5 mice.</p>
</sec>
<sec id="cns12506-sec-0012">
<title>Focused Gene Signature Profiling</title>
<p>The prognostic 35‐gene signature was implemented in the digital transcript counting (nCounter) assay (NanoString) <xref ref-type="ref" rid="cns12506-bib-0019">19</xref>. Total RNA (200–400 ng) was assayed according to the manufacturer's instructions. Data were standardized by scaling with geometric mean of built‐in control gene probes after log transformation (base 2) for each sample. Genes for testing were chosen according to the following criteria: myelin, cannabinoid, corpus callosum connectivity, and psychiatric disorders‐related genes. Probe sets for each gene were designed and synthesized by NanoString nCounter<sup>™</sup> technologies (Seattle, WA, USA) (Table S1). N = 5 mice/group.</p>
</sec>
<sec id="cns12506-sec-0013">
<title>Statistical Analysis</title>
<p>Statistical significance was evaluated by two‐way ANOVA, and a Bonferroni <italic>post hoc</italic> test was used when appropriate. Significance values were set to <italic>P</italic> &lt; 0.05. In all figures and text, data are represented as mean ± SEM. Significant effects were identified using Statistica (StatSoft Software, Tulsa, OK, USA).</p>
</sec>
</sec>
<sec id="cns12506-sec-0014">
<title>Results</title>
<sec id="cns12506-sec-0015">
<title>HOG16 Oligodendrocyte Model</title>
<p>Cells were differentiated from immature oligodendrocytes into a more mature phenotype, that is, cells that were able to synthesize myelin proteins. These cells were grown in standard medium (SM) and differentiation medium (DM) supplemented with 1 <italic>μ</italic>M of WIN, respectively (Figure <xref ref-type="fig" rid="cns12506-fig-0001">1</xref>A). Fluorescent immunocytochemistry showed a morphological change associated with differentiation. Cells changed from a round shape (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>A, i‐ii, v‐vi) to a stellated shape (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>A, iii‐iv, vii‐viii). The drug also increased the amount of myelin basic protein (MBP) under both SM and DM shown by immunofluorescence staining (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>A, v, vii). The amount of CB1 receptor increased in those cells cultured with standard medium supplemented with WIN (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>A, vi). Mbp and the cannabinoid CB1 receptor (Cnr1) gene expression were further analyzed by quantitative RT‐PCR (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>B). In brief, the cannabinoid agonist WIN promoted the expression of Mbp under either SM or DM (<italic>P</italic> &lt; 0.05; <italic>P</italic> &lt; 0.001, respectively) (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>B). Cells cultured in differentiation medium supplemented with WIN increased Mbp expression when compared with those cells grown in standard medium combined with WIN (<italic>P</italic> &lt; 0.01) (Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>B). Moreover, CB1 receptor mRNA expression increased under SM with WIN (<italic>P</italic> &lt; 0.05) as depicted in Figure <xref ref-type="fig" rid="cns12506-fig-0002">2</xref>B.</p>
<fig fig-type="Figure" id="cns12506-fig-0002" orientation="portrait" position="float" xml:lang="en">
<label>Figure 2</label>
<caption>
<p>HOG16 oligodendrocyte <italic>in vitro</italic> model. Cells were differentiated from immature oligodendrocytes to a more mature phenotype, that is, cells that were able to synthesize myelin proteins. These cells were grown in both standard medium (SM) and differentiation medium (DM) supplemented with 1 <italic>μ</italic>M of the cannabinoid CB1/CB2 agonist WIN. (<bold>A</bold>) Fluorescent immunocytochemistry showed a morphological change associated with the differentiation process. Cells changed from a round shape (i‐ii, v‐vi) to a stellated shape (iii‐iv, vii‐viii). The cannabinoid agonist WIN increased myelin basic protein expression under both SM and DM (v, vii). The CB1 receptor protein expression increased in those cells cultured with standard medium supplemented with WIN (vi). (<bold>B</bold>) The cannabinoid agonist WIN promoted the expression of Mbp under both SM and DM (<italic>P</italic> &lt; 0.05; <italic>P</italic> &lt; 0.001, respectively). Cells cultured in differentiation medium supplemented with WIN increased Mbp when compared with those cells grown in standard medium enriched with WIN (<italic>P</italic> &lt; 0.01). Finally, CB1 receptor mRNA increased in SM supplemented with WIN (<italic>P</italic> &lt; 0.05). Data are expressed as mean ± SEM. <italic>P</italic> values were set as follows: *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, and ***<italic>P</italic> &lt; 0.001. N = 3. SM, standard medium; DM, differentiation medium; Mbp, myelin basic protein; Cnr1, cannabinoid receptor 1.</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="CNS-22-387-g002"></graphic>
</fig>
</sec>
<sec id="cns12506-sec-0016">
<title>The Cuprizone Murine Model</title>
<sec id="cns12506-sec-0017">
<title>Startle Response and Prepulse Inhibition (PPI)</title>
<p>Mice exposed to CPZ for 3 weeks displayed no changes in the startle response (Figure <xref ref-type="fig" rid="cns12506-fig-0003">3</xref>i). However, we measured an increase in PPI 70 dB in CPZ‐fed mice treated with 0.5 mg/kg of WIN when compared with both control and CPZ alone (<italic>P</italic> &lt; 0.05) (Figure <xref ref-type="fig" rid="cns12506-fig-0003">3</xref>ii). In addition, CPZ‐fed mice treated with 0.5 mg/kg of WIN displayed higher PPI 75 dB than CPZ alone (<italic>P</italic> &lt; 0.05) (Figure <xref ref-type="fig" rid="cns12506-fig-0003">3</xref>iii). Mice exposed to CPZ alone shower lower score of PPI 80 dB in contrast to control and CPZ‐fed mice subjected to either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.05) (Figure <xref ref-type="fig" rid="cns12506-fig-0003">3</xref>iv). In contrast, no significant differences were found in the recovery group (data not shown).</p>
<fig fig-type="Figure" id="cns12506-fig-0003" orientation="portrait" position="float" xml:lang="en">
<label>Figure 3</label>
<caption>
<p>Startle response and prepulse inhibition (PPI) during the acute demyelination. We measured an increase in PPI 70 dB in CPZ‐fed mice treated with 0.5 mg/kg of WIN when compared with either control or CPZ alone (<italic>P</italic> &lt; 0.05) (ii). In addition, CPZ‐fed mice treated with 0.5 mg/kg of WIN displayed higher PPI 75 dB than CPZ alone (<italic>P</italic> &lt; 0.05) (iii). Mice exposed to CPZ alone declined PPI 80 dB in contrast to control and CPZ‐fed mice subjected to either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.05) (iv). Data are expressed as mean ± SEM. <italic>P</italic> values were set as follows: * <italic>P</italic> &lt; 0.05, ** <italic>P</italic> &lt; 0.01, and *** <italic>P</italic> &lt; 0.001. N = 10. CTR, control animals fed with standard diet and treated with phosphate‐buffered saline; CPZ, cuprizone‐fed animals; WIN, WIN55212.2.</p>
</caption>
<graphic id="nlm-graphic-5" xlink:href="CNS-22-387-g003"></graphic>
</fig>
</sec>
<sec id="cns12506-sec-0018">
<title>Methylene Blue/Azure II Staining and Electron Microscopy</title>
<p>Ultrastructural analysis of the corpus callosum revealed a clear demyelination after 3 weeks of CPZ alone (<italic>P</italic> &lt; 0.001) (Figure <xref ref-type="fig" rid="cns12506-fig-0004">4</xref>A, ii; B, ii; C), while CPZ‐fed mice subjected to 0.5 mg/kg of WIN showed a lower g ratio than those fed with CPZ and acutely treated with vehicle buffer (<italic>P</italic> &lt; 0.001) (Figure <xref ref-type="fig" rid="cns12506-fig-0004">4</xref>B, iii; C). In contrast, the administration of 1 mg/kg of WIN in CPZ‐fed mice induced the maximum demyelination as indicated the g ratio when compared with either controls (<italic>P</italic> &lt; 0.001), CPZ alone (<italic>P</italic> &lt; 0.001), or CPZ treated with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.001) (Figure <xref ref-type="fig" rid="cns12506-fig-0004">4</xref>B, iv; C). However, no significant differences concerning the g ratio are reported in the recovery group (Figure <xref ref-type="fig" rid="cns12506-fig-0004">4</xref>C).</p>
<fig fig-type="Figure" id="cns12506-fig-0004" orientation="portrait" position="float" xml:lang="en">
<label>Figure 4</label>
<caption>
<p>The corpus callosum cytoarchitecture. Ultrastructural analysis of the corpus callosum revealed a clear demyelination after 3 weeks of CPZ alone (<italic>P</italic> &lt; 0.001) (<bold>A</bold>‐ii, <bold>B</bold>‐ii, <bold>C</bold>), while CPZ‐fed mice subjected to 0.5 mg/kg of WIN showed a lower g ratio than those fed with CPZ and acutely treated with vehicle buffer (<italic>P</italic> &lt; 0.001) (<bold>B</bold>‐iii, <bold>C</bold>). In contrast, the administration of 1 mg/kg of WIN in CPZ‐fed mice induced the maximum demyelination as indicated the g ratio when compared with either controls (<italic>P</italic> &lt; 0.001), CPZ alone (<italic>P</italic> &lt; 0.001), or CPZ treated with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.001) (<bold>B</bold>‐iv, <bold>C</bold>). However, no significant differences concerning the g ratio are reported in the recovery group (<bold>C</bold>). Data are expressed as mean ± SEM. An § indicates significant differences between CPZ‐fed groups and their respective control group. CPZ intragroup comparisons between vehicle and drug‐treated mice are indicated by an +. Otherwise underlined * indicated comparisons between CPZ‐fed treated with 0.5 and those treated with 1 mg/kg. <italic>P</italic> values were set at <italic>P</italic> &lt; 0.001. N = 5. CTR, control animals fed with standard diet and treated with phosphate‐buffered saline; CPZ, cuprizone‐fed animals; WIN, WIN55212.2.</p>
</caption>
<graphic id="nlm-graphic-7" xlink:href="CNS-22-387-g004"></graphic>
</fig>
</sec>
<sec id="cns12506-sec-0019">
<title>Focused Gene Signature Profiling</title>
<p>The results are summarized in Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref> according to the gene expression profile data depicted in Figure S1 (3 weeks) and Figure S2 (12 weeks).</p>
<table-wrap id="cns12506-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Summary of gene expression analysis</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="2" valign="top">Time (weeks)</th>
<th align="left" colspan="1" rowspan="2" valign="top">Comparison</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Upregulated</th>
<th align="left" colspan="2" rowspan="1" style="border-bottom:solid 1px #000000" valign="top">Downregulated</th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<italic>P</italic> value</th>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<italic>P</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="4">3</td>
<td align="left" colspan="1" rowspan="1">CPZ versus CTR</td>
<td align="left" colspan="1" rowspan="1">
ApoE<break></break>
Rxra
</td>
<td align="left" char="." colspan="1" rowspan="1">
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
<td align="left" colspan="1" rowspan="1">
Mbp<break></break>
Mog<break></break>
Mag<break></break>
Napepld
</td>
<td align="left" char="." colspan="1" rowspan="1">
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CPZ+0.5 versus CTR</td>
<td align="left" colspan="1" rowspan="1">
ApoE<break></break>
Rxra
</td>
<td align="left" char="." colspan="1" rowspan="1">
&lt;0.001<xref ref-type="fn" rid="cns12506-note-0003">***</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
</td>
<td align="left" colspan="1" rowspan="1">
NogoR<break></break>
Mog<break></break>
Mbp<break></break>
Mag<break></break>
Satb2<break></break>
Napepld<break></break>
Dagla<break></break>
Vgf
</td>
<td align="left" char="." colspan="1" rowspan="1">
&lt;0.001<xref ref-type="fn" rid="cns12506-note-0003">***</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CPZ+1 versus CTR</td>
<td align="left" colspan="1" rowspan="1">ApoE</td>
<td align="left" char="." colspan="1" rowspan="1">&lt;0.001<xref ref-type="fn" rid="cns12506-note-0003">***</xref>
</td>
<td align="left" colspan="1" rowspan="1">
NogoR<break></break>
Napepld<break></break>
Mog<break></break>
Mag<break></break>
Mbp<break></break>
Cnp<break></break>
Vgf<break></break>
Satb2<break></break>
Calr
</td>
<td align="left" char="." colspan="1" rowspan="1">
&lt;0.001<xref ref-type="fn" rid="cns12506-note-0003">***</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CPZ+1 versus CPZ+0.5</td>
<td align="left" colspan="1" rowspan="1">Ski</td>
<td align="left" char="." colspan="1" rowspan="1">&lt;0.01<xref ref-type="fn" rid="cns12506-note-0003">**</xref>
</td>
<td align="left" colspan="2" rowspan="1">NS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">12</td>
<td align="left" colspan="1" rowspan="1">CPZ+0.5 versus CPZ</td>
<td align="left" colspan="2" rowspan="1">NS</td>
<td align="left" char="." colspan="1" rowspan="1">
Mag<break></break>
Olig2
</td>
<td align="left" colspan="1" rowspan="1">
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CPZ+1 versus CPZ</td>
<td align="left" colspan="1" rowspan="1">Dtnbp1</td>
<td align="left" char="." colspan="1" rowspan="1">&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
<td align="left" colspan="1" rowspan="1">
Olig2<break></break>
Sox10<break></break>
Mag<break></break>
Calr<break></break>
Ddr1
</td>
<td align="left" char="." colspan="1" rowspan="1">
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
<break></break>
&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CPZ+1 versus CPZ+0.5</td>
<td align="left" colspan="1" rowspan="1">Dtnbp1</td>
<td align="left" char="." colspan="1" rowspan="1">&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
<td align="left" colspan="1" rowspan="1">Olig2</td>
<td align="left" char="." colspan="1" rowspan="1">&lt;0.05<xref ref-type="fn" rid="cns12506-note-0003">*</xref>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="cns12506-note-0002">
<p>
<italic>Time</italic> = 3<italic>:</italic> apolipoprotein E (ApoE) expression increased following CPZ alone (<italic>P</italic> &lt; 0.01) and in combination with either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.001). Moreover, the expression of myelin oligodendrocyte glycoprotein (Mog), myelin basic protein (Mbp), and myelin‐associated glycoprotein (Mag) declined following cuprizone alone (<italic>P</italic> &lt; 0.05) or in combination with either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.01). Animals exposed to CPZ diet and treated with either 0.5 or 1 mg/kg of WIN exhibited lower expression of Nogo receptor (Ngr1) (<italic>P</italic> &lt; 0.001), special AT‐rich sequence‐binding protein 2 (Satb2) (<italic>P</italic> &lt; 0.01; <italic>P</italic> &lt; 0.05, respectively), and nerve growth factor inducible (Vgf) (<italic>P</italic> &lt; 0.05). In addition, the administration of 1 mg/kg WIN in CPZ‐fed animals decreased specifically the expression of 2′,3′‐cyclic nucleotide 3′ phosphodiesterase (Cnp) and also does calreticulin (Calr) (<italic>P</italic> &lt; 0.05). <italic>Time </italic>= 12<italic>:</italic> the expression of Mag and Olig2 decreased following CPZ feeding and 0.5 mg/kg of WIN in contrast to CPZ alone (<italic>P</italic> &lt; 0.05). The recovery group exposed to 1 mg/kg WIN showed lower Olig2, Sox10, Mag, Calr, and discoidin domain receptor 1 (Ddr1) expression in comparison with CPZ alone (<italic>P</italic> &lt; 0.05). Furthermore, the expression of Olig2 decreased in CPZ‐fed mice treated with 1 mg/kg of WIN when compared with those mice treated with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.05). The remaining comparisons are depicted in the table.</p>
</fn>
<fn id="cns12506-note-0003">
<p>
<italic>P</italic> values were set as follows: NS (<italic>P</italic> &gt; 0.05), *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, and ***<italic>P</italic> &lt; 0.001. N = 5. CTR, control animals fed with standard diet and treated with phosphate‐buffered saline; CPZ, cuprizone‐fed animals.</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>During the acute demyelination, apolipoprotein E (ApoE) expression increased following both CPZ alone (<italic>P</italic> &lt; 0.01) and CPZ combined with either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.001) when compared with their respective controls as depicted in Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>. The administration of cuprizone increased the expression of retinoid × receptor alpha (Rxra) in mice exposed to vehicle (CPZ alone) as well as in combination with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.01) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). Moreover, the expression of myelin oligodendrocyte glycoprotein (Mog), myelin basic protein (Mbp), myelin‐associated glycoprotein (Mag), and N‐acyl phosphatidylethanolamine phospholipase D (Napepld) declined following cuprizone alone (<italic>P</italic> &lt; 0.05) or in combination with either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.01) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). Animals exposed to CPZ diet and treated with either 0.5 or 1 mg/kg of WIN exhibited lower expression of nogo receptor (Ngr1) (<italic>P</italic> &lt; 0.001), special AT‐rich sequence‐binding protein 2 (Satb2) (<italic>P</italic> &lt; 0.01; <italic>P</italic> &lt; 0.05, respectively), and nerve growth factor inducible (Vgf) (<italic>P</italic> &lt; 0.05) than controls (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). Daily injection with 0.5 mg/kg of WIN in CPZ‐fed mice decreased the expression of diacylglycerol lipase alpha (Dagla) in contrast to controls (<italic>P</italic> &lt; 0.05) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). In addition, the administration of 1 mg/kg WIN in CPZ‐fed animals reduced the expression of 2′,3′‐cyclic nucleotide 3′ phosphodiesterase (Cnp) and also does calreticulin (Calr) (<italic>P</italic> &lt; 0.05) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). CPZ‐fed mice subjected to 1 mg/kg of WIN displayed higher Ski protooncogene (Ski) expression than those mice treated with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.01) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>).</p>
<p>After a recovery period of 6 weeks following cuprizone dietary, dystrobrevin binding protein 1 (Dtnbp1) expression was higher in mice treated with 1 mg/kg of WIN when compared with either CPZ alone or CPZ combined with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.05) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). Furthermore, Mag and oligodendrocyte transcription factor (Olig2) expression were downregulated following CPZ feeding and 0.5 mg/kg of WIN in contrast to CPZ alone (<italic>P</italic> &lt; 0.05) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). The recovery group exposed to 1 mg/kg of WIN showed lower Olig2, Mag, SRY‐Box 10 (Sox10), Calr, and discoidin domain receptor 1 (Ddr1) expression in comparison with CPZ alone (<italic>P</italic> &lt; 0.05) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>). In addition, the expression of Olig2 decreased in CPZ‐fed mice treated with 1 mg/kg of WIN when compared with those animals treated with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.05) (Table <xref ref-type="table" rid="cns12506-tbl-0001">1</xref>).</p>
</sec>
</sec>
</sec>
<sec id="cns12506-sec-0020">
<title>Discussion</title>
<p>After confirming the presence of CB1 receptor in a cultured oligodendrocyte cell line, we also proved that the synthetic cannabinoid agonist WIN exerted a strong effect on immature oligodendrocytes resulting in increased MBP levels 24 h once the differentiation process started, in agreement with Gomez et al. <xref ref-type="ref" rid="cns12506-bib-0004">4</xref>. This fact encouraged us to investigate the effect of WIN in a well‐described mouse model of demyelination, the cuprizone model <xref ref-type="ref" rid="cns12506-bib-0003">3</xref>. Here, we focused our study on the acute demyelination and the recovery period.</p>
<sec id="cns12506-sec-0021">
<title>Acute Demyelination</title>
<p>CPZ‐fed mice exhibited PPI deficits that were reversed by 0.5 mg/kg of WIN. Despite this, Xu et al. <xref ref-type="ref" rid="cns12506-bib-0020">20</xref> reported that mice exposed to CPZ for 3 weeks displayed lower prepulse inhibition as well as higher dopamine levels <xref ref-type="ref" rid="cns12506-bib-0020">20</xref>. Overactivation of dopaminergic system in the forebrain correlates with PPI deficits in humans <xref ref-type="ref" rid="cns12506-bib-0021">21</xref> and also in animals <xref ref-type="ref" rid="cns12506-bib-0020">20</xref>. The cannabinoids are actively involved in dopamine release in the prefrontal cortex <xref ref-type="ref" rid="cns12506-bib-0022">22</xref>. Furthermore, ultrastructural analysis of the corpus callosum revealed more myelinated axons following 3 weeks of CPZ diet combined with 0.5 mg/kg, but not in those mice treated with 1 mg/kg. In fact, many studies have demonstrated either therapeutic or deleterious effects of cannabinoids on the viability of various cell types (for review, see <xref ref-type="ref" rid="cns12506-bib-0023">23</xref> that might be attributable to blockage or stimulation of calcium entry into the cell, which in turn depends on cannabinoid concentration <xref ref-type="ref" rid="cns12506-bib-0024">24</xref>.</p>
<p>In neurodegenerative processes, CNS cholesterol synthesis is compromised. ApoE plays an important role in CNS cholesterol and lipid metabolism <xref ref-type="ref" rid="cns12506-bib-0025">25</xref>. Therefore, the dysregulation of the endocannabinoid system has been associated with ApoE activity <xref ref-type="ref" rid="cns12506-bib-0026">26</xref>. Recent reports suggest that demyelination in experimental allergic encephalomyelitis (EAE) is related to an increase in ApoE <xref ref-type="ref" rid="cns12506-bib-0025">25</xref>, which supports the present findings. In addition, retinoid acids (rxrs) are essential for cholesterol metabolism <xref ref-type="ref" rid="cns12506-bib-0027">27</xref>, <xref ref-type="ref" rid="cns12506-bib-0028">28</xref> and stimulate oligodendrocyte differentiation <xref ref-type="ref" rid="cns12506-bib-0029">29</xref>. Interestingly, we found that 0.5 mg/kg of WIN during CPZ exposure increased the expression of Rxra which might protect myelinated axons against cuprizone. In contrast, the drug at 1 mg/kg aggravates CNS demyelination as indicated ultrastructural and gene expression analysis. Particularly, CPZ‐fed animals subjected to 1 mg/kg displayed a decrease in the expression of myelin‐related genes and also Cnp. Cnpase is involved in RNA trafficking, splicing, and metabolism in the myelinating oligodendrocyte <xref ref-type="ref" rid="cns12506-bib-0030">30</xref>, <xref ref-type="ref" rid="cns12506-bib-0031">31</xref>, <xref ref-type="ref" rid="cns12506-bib-0032">32</xref>, <xref ref-type="ref" rid="cns12506-bib-0033">33</xref>. The severity of demyelination in EAE model is modulated by CB1 receptor <xref ref-type="ref" rid="cns12506-bib-0034">34</xref>, <xref ref-type="ref" rid="cns12506-bib-0035">35</xref>, which underpins the present findings. Furthermore, we reported lower Napepld expression in all groups fed with CPZ and this fact might indicate less AEA content. However, previous studies revealed decreased AEA levels <xref ref-type="ref" rid="cns12506-bib-0036">36</xref>, whereas others observed normal <xref ref-type="ref" rid="cns12506-bib-0037">37</xref> or higher <xref ref-type="ref" rid="cns12506-bib-0038">38</xref> AEA levels in demyelinated brains. In addition, the gene involved in 2‐AG synthesis (Dagla) was declined following CPZ diet and 0.5 mg/kg of WIN although others have found conflicting results <xref ref-type="ref" rid="cns12506-bib-0039">39</xref>, <xref ref-type="ref" rid="cns12506-bib-0040">40</xref>, <xref ref-type="ref" rid="cns12506-bib-0041">41</xref>, <xref ref-type="ref" rid="cns12506-bib-0042">42</xref>. This discrepancy might be attributed to the animal model (rats vs. mice), the methods, the sampling time applied, or the target brain structure analyzed.</p>
<p>Administration of CPZ in combination with 0.5 mg/kg of WIN decreased the expression of NgR1 and might confer neuroprotection against CPZ. In fact, NgR1 participates in oligodendrocyte differentiation, myelination <xref ref-type="ref" rid="cns12506-bib-0043">43</xref>, and cell cytoskeleton reorganization <xref ref-type="ref" rid="cns12506-bib-0044">44</xref>, while the blockade of NgR1 signaling prevents axonal degeneration in EAE model <xref ref-type="ref" rid="cns12506-bib-0044">44</xref>. Accordingly, it is noteworthy to speculate that the loss of NgR1 might protect the axon.</p>
<p>Animals fed with CPZ and subjected to either 0.5 or 1 mg/kg of WIN might suffer a dysfunction in the corticocortical connectivity resulting from a downregulation of Satb2 expression. DNA‐binding protein Satb2 is essential for the normal elaboration of corticocortical network <xref ref-type="ref" rid="cns12506-bib-0045">45</xref>. During the acute demyelination, the expression of Ski protooncogene increased following CPZ diet and 1 mg/kg of WIN when compared with those animals subjected to 0.5 mg/kg. Such increase might contribute to counteract the exacerbated demyelination observed after CPZ dietary combined with 1 mg/kg of WIN. In line with these findings, it is described that neurons for Ski‐deficient mice lose their identity and cannot culminate to form the corpus callosum <xref ref-type="ref" rid="cns12506-bib-0046">46</xref>.</p>
<p>The present findings demonstrated lower Vgf expression following the administration of CPZ combined with either 0.5 or 1 mg/kg of WIN, but not after CPZ alone. Vgf is a component of the chromogranin/secretogranin family <xref ref-type="ref" rid="cns12506-bib-0047">47</xref>, <xref ref-type="ref" rid="cns12506-bib-0048">48</xref> actively involved in amyotrophic lateral sclerosis (ALS) neuroprotection <xref ref-type="ref" rid="cns12506-bib-0049">49</xref>. Because it is described that declined levels of this bioactive peptide (Vgf) could promote neurodegeneration <xref ref-type="ref" rid="cns12506-bib-0050">50</xref>, further investigation of these aspects is required.</p>
<p>Proteins associated with endoplasmic reticulum (ER) stress have recently been shown in demyelinating disorders <xref ref-type="ref" rid="cns12506-bib-0051">51</xref>, <xref ref-type="ref" rid="cns12506-bib-0052">52</xref>. Among these, the chaperone Calr has an important role in serum myelin clearance <xref ref-type="ref" rid="cns12506-bib-0053">53</xref>. Indeed, we assume that CPZ‐fed mice treated with 1 mg/kg of WIN showed an impairment in serum myelin clearance as indicated the loss of Calr expression <xref ref-type="ref" rid="cns12506-bib-0053">53</xref>.</p>
</sec>
<sec id="cns12506-sec-0022">
<title>The Recovery Period</title>
<p>Animals fed with normal chow for a recovery period of 6 weeks following cuprizone diet displayed no differences regarding sensory motor gaiting, while the corpus callosum was apparently normal <xref ref-type="ref" rid="cns12506-bib-0003">3</xref>. However, certain genes persisted deregulated. Briefly, animals exposed to CPZ and treated with either 0.5 or 1 mg/kg of WIN declined the expression of Mag in comparison with CPZ alone and this fact might indicate a failure in the trophic support for oligodendrocytes <xref ref-type="ref" rid="cns12506-bib-0054">54</xref>. After a recovery period of 6 weeks, once CPZ was removed from diet, 1 mg/kg of WIN declined the expression of myelin‐related genes such as Olig2, Sox10, and Ddr1 in comparison with CPZ alone. The proliferation of OPCs at the demyelinated region is tightly coordinated by a complex interplay of intrinsic, extrinsic, and epigenetic mechanisms <xref ref-type="ref" rid="cns12506-bib-0055">55</xref>. Among the intrinsic factors, Olig2 and Sox10 are critical for oligodendrocytes <xref ref-type="ref" rid="cns12506-bib-0056">56</xref>, <xref ref-type="ref" rid="cns12506-bib-0057">57</xref>. An overexpression of Ddr1 has been reported in myelinating oligodendrocytes <xref ref-type="ref" rid="cns12506-bib-0058">58</xref>, during oligodendrocyte differentiation as well as during CPZ‐induced remyelination <xref ref-type="ref" rid="cns12506-bib-0014">14</xref>. Accordingly, we demonstrated that myelin‐related processes are affected by 1 mg/kg WIN during both demyelination and recovery period. Additionally, we found that Olig2 remained downregulated in CPZ‐fed animals treated with 1 mg/kg in comparison with those treated with 0.5 mg/kg, which in turn supports that myelination is not fully achieved.</p>
<p>Following CPZ and 1 mg/kg of WIN, Dtnbp1 expression increased in comparison with the remaining CPZ‐fed animals, which could promote neurite outgrowth and cytoskeleton rearrangements in order to restore corpus callosum connectivity. In fact, Dtnbp1 regulates neurotransmitter release, signal transduction <xref ref-type="ref" rid="cns12506-bib-0059">59</xref>, while deficits in this protein cause shorter neurite length and alterations in cytoskeleton rearrangements <xref ref-type="ref" rid="cns12506-bib-0060">60</xref>. Moreover, ER homeostasis and serum myelin clearance might be at risk following CPZ and 1 mg/kg of WIN compared with CPZ alone as indicated the loss of calreticulin expression <xref ref-type="ref" rid="cns12506-bib-0053">53</xref>.</p>
<p>In conclusion, we proved that the drug WIN promotes oligodendrocyte differentiation <italic>in vitro</italic>. During the CPZ‐induced CNS demyelination, we assessed a neuroprotective effect of 0.5 mg/kg of the drug as shown by (1) better sensory motor gaiting, (2) more myelinated axons/area, and (3) overexpression of Rxra in combination with lower NgR1 expression. In contrast, CPZ‐fed mice treated with 1 mg/kg of WIN exhibited the maximum demyelination as indicated by (1) more demyelination axons/area and (2) downregulation of Vgf, Calr, and myelin‐related gene expression coupling specifically with lower Cnp expression. However, the detailed mechanisms of action that underlie the cannabinoid neuroprotection warrant further investigation.</p>
</sec>
</sec>
<sec id="cns12506-sec-0024" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare no conflict of interest.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data">
<caption>
<p>
<bold>Table S1.</bold> Nanostring nCounter codeset. Column titles from left to right: official gene symbol; target sequence; accession.</p>
</caption>
<media xlink:href="CNS-22-387-s001.tiff">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data">
<caption>
<p>
<bold>Figure S1.</bold> Nanostring nCounter gene expression profile at the third week. During the acute demyelination, ApoE expression increased following CPZ alone (<italic>P</italic> &lt; 0.01) and in combination with either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.001). The administration of cuprizone increased the expression of Rxra in mice exposed to vehicle (CPZ alone) as well as in combination with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.01). Moreover, the expression of Mog, Mbp, Mag, and Napepld were declined following CPZ alone (<italic>P</italic> &lt; 0.05) or in combination with either 0.5 or 1 mg/kg of WIN (<italic>P</italic> &lt; 0.01). Animals exposed to CPZ diet and treated with either 0.5 or 1 mg/kg of WIN exhibited lower expression of Ngr1 (<italic>P</italic> &lt; 0.001), Satb2 (<italic>P</italic> &lt; 0.01; <italic>P</italic> &lt; 0.05, respectively), and Vgf (<italic>P</italic> &lt; 0.05). Daily injection with 0.5 mg/kg of WIN in CPZ‐fed mice decreased the expression of Dagla in contrast to controls (<italic>P</italic> &lt; 0.05). In addition, the administration of 1 mg/kg WIN in CPZ‐fed animals decreased specifically the expression of Cnp and also does Calr (<italic>P</italic> &lt; 0.05). CPZ‐fed mice subjected to 1 mg/kg of WIN displayed higher Ski expression than those mice treated with 0.5 mg/kg (<italic>P</italic> &lt; 0.01). The remaining comparisons were statistically nonsignificant and not included in this figure. Data were normalized by scaling with geometric mean of built‐in control gene probes after log transformation (base 2) for each sample. Level of significance (‐log10p) was set to *1.30103, **2, and ***3. –Log2FC values below 0 indicate downregulation, whereas upper 0 indicate upregulation. N = 5. CTR, control animals fed with standard diet and treated with phosphate‐buffered saline; CPZ, cuprizone‐fed animals.</p>
</caption>
<media xlink:href="CNS-22-387-s002.tiff">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data">
<caption>
<p>
<bold>Figure S2.</bold> Nanostring nCounter gene expression profile at the twelfth week. After a recovery period of 6 weeks following cuprizone dietary, Dtnbp1 expression increased in CPZ‐fed mice treated with 1 mg/kg of WIN when compared with either CPZ alone or in combination with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.05). Furthermore, Mag and Olig2 expression underwent a downregulation following CPZ feeding and 0.5 mg/kg of WIN in contrast to CPZ alone (<italic>P</italic> &lt; 0.05). The recovery group exposed to 1 mg/kg of WIN showed lower Olig2, Sox10, Mag, Calr, and Ddr1 expression in comparison with CPZ alone (<italic>P</italic> &lt; 0.05). In addition, the expression of Olig2 decreased in CPZ‐fed mice treated with 1 mg/kg of WIN when compared with those mice treated with 0.5 mg/kg of WIN (<italic>P</italic> &lt; 0.05). The remaining comparisons were statistically nonsignificant and not included in this figure. Data were normalized by scaling with geometric mean of built‐in control gene probes after log transformation (base 2) for each sample. Level of significance (‐log<sub>10</sub>p) was set to *1.30103, **2, and ***3. –Log<sub>2</sub>FC values below 0 indicate downregulation, whereas upper 0 indicate upregulation. N = 5. CTR, control animals fed with standard diet and treated with phosphate‐buffered saline; CPZ, cuprizone‐fed animals.</p>
</caption>
<media xlink:href="CNS-22-387-s003.tiff">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack id="cns12506-sec-0023">
<title>Acknowledgment</title>
<p>The authors would like to thank Dr. Möbius and Torben Ruhwedel (Dept. of Neurogenetics, MPIEM, Göttingen, Germany) for excellent technical support. The work was supported by DFG CNMPB grant CNMPB C1‐6 to Prof Havemann‐Reinecke. We thank the Northern German Addiction Research Federation for kindly financial support of this study to U. Havemann‐Reinecke.</p>
</ack>
<ref-list content-type="cited-references" id="cns12506-bibl-0001">
<title>References</title>
<ref id="cns12506-bib-0001">
<label>1</label>
<mixed-citation id="cns12506-cit-0001" publication-type="journal">
<string-name>
<surname>Baumann</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Pham‐Dinh</surname>
<given-names>D</given-names>
</string-name>. <article-title>Biology of oligodendrocyte and myelin in the mammalian central nervous system</article-title>. <source xml:lang="en"/>Physiol Rev
<year>2001</year>;<volume>81</volume>:<fpage>871</fpage>–<lpage>927</lpage>.<pub-id pub-id-type="pmid">11274346</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0002">
<label>2</label>
<mixed-citation id="cns12506-cit-0002" publication-type="journal">
<string-name>
<surname>Waxman</surname>
<given-names>SG</given-names>
</string-name>. <article-title>Axonal conduction and injury in multiple sclerosis: The role of sodium channels</article-title>. <source xml:lang="en"/>Nat Rev Neurosci
<year>2006</year>;<volume>7</volume>:<fpage>932</fpage>–<lpage>941</lpage>.<pub-id pub-id-type="pmid">17115075</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0003">
<label>3</label>
<mixed-citation id="cns12506-cit-0003" publication-type="journal">
<string-name>
<surname>Matsushima</surname>
<given-names>GK</given-names>
</string-name>, <string-name>
<surname>Morell</surname>
<given-names>P</given-names>
</string-name>. <article-title>The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system</article-title>. <source xml:lang="en"/>Brain Pathol
<year>2001</year>;<volume>11</volume>:<fpage>107</fpage>–<lpage>116</lpage>.<pub-id pub-id-type="pmid">11145196</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0004">
<label>4</label>
<mixed-citation id="cns12506-cit-0004" publication-type="journal">
<string-name>
<surname>Gomez</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Rodriguez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sanchez‐Caro</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Molina‐Holgado</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Molina‐Holgado</surname>
<given-names>E</given-names>
</string-name>. <article-title>Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways</article-title>. <source xml:lang="en"/>Br J Pharmacol
<year>2011</year>;<volume>163</volume>:<fpage>1520</fpage>–<lpage>1532</lpage>.<pub-id pub-id-type="pmid">21480865</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0005">
<label>5</label>
<mixed-citation id="cns12506-cit-0005" publication-type="journal">
<string-name>
<surname>Vettor</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pagano</surname>
<given-names>C</given-names>
</string-name>. <article-title>The role of the endocannabinoid system in lipogenesis and fatty acid metabolism</article-title>. <source xml:lang="en"/>Best Pract Res: Clin Endocrinol Metab
<year>2009</year>;<volume>23</volume>:<fpage>51</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">19285260</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0006">
<label>6</label>
<mixed-citation id="cns12506-cit-0006" publication-type="journal">
<string-name>
<surname>Smith</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Sim‐Selley</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Selley</surname>
<given-names>DE</given-names>
</string-name>. <article-title>Cannabinoid CB1 receptor‐interacting proteins: Novel targets for central nervous system drug discovery?</article-title>
<source xml:lang="en"/>Br J Pharmacol
<year>2010</year>;<volume>160</volume>:<fpage>454</fpage>–<lpage>466</lpage>.<pub-id pub-id-type="pmid">20590557</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0007">
<label>7</label>
<mixed-citation id="cns12506-cit-0007" publication-type="journal">
<string-name>
<surname>Ruehle</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rey</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Remmers</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lutz</surname>
<given-names>B</given-names>
</string-name>. <article-title>The endocannabinoid system in anxiety, fear memory and habituation</article-title>. <source xml:lang="en"/>J Psychopharmacol
<year>2012</year>;<volume>26</volume>:<fpage>23</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">21768162</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0008">
<label>8</label>
<mixed-citation id="cns12506-cit-0008" publication-type="journal">
<string-name>
<surname>Devane</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Hanus</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Breuer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Isolation and structure of a brain constituent that binds to the cannabinoid receptor</article-title>. <source xml:lang="en"/>Science
<year>1992</year>;<volume>258</volume>:<fpage>1946</fpage>–<lpage>1949</lpage>.<pub-id pub-id-type="pmid">1470919</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0009">
<label>9</label>
<mixed-citation id="cns12506-cit-0009" publication-type="journal">
<string-name>
<surname>Sugiura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kondo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sukagawa</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>2‐Arachidonoylgylcerol: A possible endogenous cannabinoid receptor ligand in brain</article-title>. <source xml:lang="en"/>Biochem Biophys Res Commun
<year>1995</year>;<volume>215</volume>:<fpage>89</fpage>–<lpage>97</lpage>.<pub-id pub-id-type="pmid">7575630</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0010">
<label>10</label>
<mixed-citation id="cns12506-cit-0010" publication-type="journal">
<string-name>
<surname>Basavarajappa</surname>
<given-names>BS</given-names>
</string-name>. <article-title>Critical enzymes involved in endocannabinoid metabolism</article-title>. <source xml:lang="en"/>Protein Pept Lett
<year>2007</year>;<volume>14</volume>:<fpage>237</fpage>–<lpage>246</lpage>.<pub-id pub-id-type="pmid">17346227</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0011">
<label>11</label>
<mixed-citation id="cns12506-cit-0011" publication-type="journal">
<string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>. <article-title>Endocannabinoids: Synthesis and degradation</article-title>. <source xml:lang="en"/>Rev Physiol Biochem Pharmacol
<year>2008</year>;<volume>160</volume>:<fpage>1</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">18481028</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0012">
<label>12</label>
<mixed-citation id="cns12506-cit-0012" publication-type="journal">
<string-name>
<surname>Rapp</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Walter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Studerus</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Cannabis use and brain structural alterations of the cingulate cortex in early psychosis</article-title>. <source xml:lang="en"/>Psychiatry Res
<year>2013</year>;<volume>214</volume>:<fpage>102</fpage>–<lpage>108</lpage>.<pub-id pub-id-type="pmid">24054726</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0013">
<label>13</label>
<mixed-citation id="cns12506-cit-0013" publication-type="journal">
<string-name>
<surname>Sánchez‐Blázquez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rodríguez‐Muñoz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Garzón</surname>
<given-names>J</given-names>
</string-name>. <article-title>The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: Implications in psychosis and schizophrenia</article-title>. <source xml:lang="en"/>Front Pharmacol
<year>2013</year>;<volume>4</volume>:<fpage>169</fpage>.</mixed-citation>
</ref>
<ref id="cns12506-bib-0014">
<label>14</label>
<mixed-citation id="cns12506-cit-0014" publication-type="journal">
<string-name>
<surname>Franco‐Pons</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tomàs</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Roig</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Auladell</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Martorell</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Vilella</surname>
<given-names>E</given-names>
</string-name>. <article-title>Discoidin domain receptor 1, a tyrosine kinase receptor, is upregulated in an experimental model of remyelination and during oligodendrocyte differentiation in vitro</article-title>. <source xml:lang="en"/>J Mol Neurosci
<year>2009</year>;<volume>38</volume>:<fpage>2</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">18836851</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0015">
<label>15</label>
<mixed-citation id="cns12506-cit-0015" publication-type="journal">
<string-name>
<surname>Bologov</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gafni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Keren</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Sarne</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro</article-title>. <source xml:lang="en"/>Cell Mol Neurobiol
<year>2011</year>;<volume>31</volume>:<fpage>195</fpage>–<lpage>202</lpage>.<pub-id pub-id-type="pmid">21052827</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0016">
<label>16</label>
<mixed-citation id="cns12506-cit-0016" publication-type="journal">
<string-name>
<surname>Radyushkin</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hammerschmidt</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Boretius</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Neuroligin‐3‐deficient mice: Model of a monogenic heritable form of autism with an olfactory deficit</article-title>. <source xml:lang="en"/>Genes Brain Behav
<year>2009</year>;<volume>8</volume>:<fpage>416</fpage>–<lpage>425</lpage>.<pub-id pub-id-type="pmid">19243448</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0017">
<label>17</label>
<mixed-citation id="cns12506-cit-0017" publication-type="journal">
<string-name>
<surname>Schultz</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Karlsson</surname>
<given-names>U</given-names>
</string-name>. <article-title>Fixation of the central nervous system for electron microscopy by aldehyde perfusion. II. Effect of osmolarity, pH of perfusate, and fixative concentration</article-title>. <source xml:lang="en"/>J Ultrastruct Res
<year>1965</year>;<volume>12</volume>:<fpage>187</fpage>–<lpage>206</lpage>.<pub-id pub-id-type="pmid">14289427</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0018">
<label>18</label>
<mixed-citation id="cns12506-cit-0018" publication-type="journal">
<string-name>
<surname>Reynolds</surname>
<given-names>E</given-names>
</string-name>. <article-title>The use of lead citrate at high pH as an electron‐opaque stain in electron microscopy</article-title>. <source xml:lang="en"/>J Cell Biol
<year>1963</year>;<volume>17</volume>:<fpage>208</fpage>–<lpage>212</lpage>.<pub-id pub-id-type="pmid">13986422</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0019">
<label>19</label>
<mixed-citation id="cns12506-cit-0019" publication-type="journal">
<string-name>
<surname>Hoshida</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Villanueva</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sangiovanni</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Prognostic gene expression signature for patients with hepatitis C‐related early‐stage cirrhosis</article-title>. <source xml:lang="en"/>Gastroenterology
<year>2013</year>;<volume>144</volume>:<fpage>1024</fpage>–<lpage>1030</lpage>.<pub-id pub-id-type="pmid">23333348</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0020">
<label>20</label>
<mixed-citation id="cns12506-cit-0020" publication-type="journal">
<string-name>
<surname>Xu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>H‐J</given-names>
</string-name>, <string-name>
<surname>McConomy</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Browning</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X‐M</given-names>
</string-name>. <article-title>Behavioral and neurobiological changes in C57BL/6 mouse exposed to cuprizone: Effects of antipsychotics</article-title>. <source xml:lang="en"/>Front Behav Neurosci
<year>2010</year>;<volume>4</volume>:<fpage>8</fpage>.<pub-id pub-id-type="pmid">20305752</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0021">
<label>21</label>
<mixed-citation id="cns12506-cit-0021" publication-type="journal">
<string-name>
<surname>Swerdlow</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Stephany</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wasserman</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Talledo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shoemaker</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Auerbach</surname>
<given-names>PP</given-names>
</string-name>. <article-title>Amphetamine effects on prepulse inhibition across‐species: Replication and parametric extension</article-title>. <source xml:lang="en"/>Neuropsychopharmacology
<year>2003</year>;<volume>28</volume>:<fpage>640</fpage>–<lpage>650</lpage>.<pub-id pub-id-type="pmid">12655308</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0022">
<label>22</label>
<mixed-citation id="cns12506-cit-0022" publication-type="journal">
<string-name>
<surname>Pistis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ferraro</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pira</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Delta(9)‐tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: An in vivo microdialysis study</article-title>. <source xml:lang="en"/>Brain Res
<year>2002</year>;<volume>948</volume>:<fpage>155</fpage>–<lpage>158</lpage>.<pub-id pub-id-type="pmid">12383968</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0023">
<label>23</label>
<mixed-citation id="cns12506-cit-0023" publication-type="journal">
<string-name>
<surname>Guzmán</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sánchez</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Galve‐Roperh</surname>
<given-names>I</given-names>
</string-name>. <article-title>Cannabinoids and cell fate</article-title>. <source xml:lang="en"/>Pharmacol Ther
<year>2002</year>;<volume>95</volume>:<fpage>175</fpage>–<lpage>184</lpage>.<pub-id pub-id-type="pmid">12182964</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0024">
<label>24</label>
<mixed-citation id="cns12506-cit-0024" publication-type="journal">
<string-name>
<surname>Rubovitch</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gafni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sarne</surname>
<given-names>Y</given-names>
</string-name>. <article-title>The cannabinoid agonist DALN positively modulates L‐type voltage‐dependent calcium‐channels in N18TG2 neuroblastoma cells</article-title>. <source xml:lang="en"/>Mol Brain Res
<year>2002</year>;<volume>101</volume>:<fpage>93</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">12007836</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0025">
<label>25</label>
<mixed-citation id="cns12506-cit-0025" publication-type="journal">
<string-name>
<surname>Dayger</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Rosenberg</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Winkler</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Paradoxical effects of apolipoprotein E on cognitive function and clinical progression in mice with experimental autoimmune encephalomyelitis</article-title>. <source xml:lang="en"/>Pharmacol Biochem Behav
<year>2012</year>; DOI: S0091‐3057(12)00321‐8 [pii]\r10.1016/j.pbb.2012.11.010.</mixed-citation>
</ref>
<ref id="cns12506-bib-0026">
<label>26</label>
<mixed-citation id="cns12506-cit-0026" publication-type="journal">
<string-name>
<surname>Bartelt</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Orlando</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mele</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Altered endocannabinoid signalling after a high‐fat diet in Apoe ‐/‐ mice: Relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance</article-title>. <source xml:lang="en"/>Diabetologia
<year>2011</year>;<volume>54</volume>:<fpage>2900</fpage>–<lpage>2910</lpage>.<pub-id pub-id-type="pmid">21847582</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0027">
<label>27</label>
<mixed-citation id="cns12506-cit-0027" publication-type="journal">
<string-name>
<surname>Diab</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hussain</surname>
<given-names>RZ</given-names>
</string-name>, <string-name>
<surname>Lovett‐Racke</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Chavis</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Drew</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Racke</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Ligands for the peroxisome proliferator‐activated receptor‐gamma and the retinoid X receptor exert additive anti‐inflammatory effects on experimental autoimmune encephalomyelitis</article-title>. <source xml:lang="en"/>J Neuroimmunol
<year>2004</year>;<volume>148</volume>:<fpage>116</fpage>–<lpage>126</lpage>.<pub-id pub-id-type="pmid">14975592</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0028">
<label>28</label>
<mixed-citation id="cns12506-cit-0028" publication-type="journal">
<string-name>
<surname>Gentili</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tutolo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Pianezzi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cancedda</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Cancedda</surname>
<given-names>FD</given-names>
</string-name>. <article-title>Cholesterol secretion and homeostasis in chondrocytes: A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression</article-title>. <source xml:lang="en"/>Matrix Biol
<year>2005</year>;<volume>24</volume>:<fpage>35</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">15749000</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0029">
<label>29</label>
<mixed-citation id="cns12506-cit-0029" publication-type="journal">
<string-name>
<surname>Huang</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Jarjour</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Nait Oumesmar</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Retinoid X receptor gamma signaling accelerates CNS remyelination</article-title>. <source xml:lang="en"/>Nat Neurosci
<year>2011</year>;<volume>14</volume>:<fpage>45</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">21131950</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0030">
<label>30</label>
<mixed-citation id="cns12506-cit-0030" publication-type="journal">
<string-name>
<surname>Bifulco</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Laezza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Stingo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wolff</surname>
<given-names>J</given-names>
</string-name>. <article-title>2′,3′‐Cyclic nucleotide 3′‐phosphodiesterase: A membrane‐bound, microtubule‐associated protein and membrane anchor for tubulin</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci USA
<year>2002</year>;<volume>99</volume>:<fpage>1807</fpage>–<lpage>1812</lpage>.<pub-id pub-id-type="pmid">11842207</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0031">
<label>31</label>
<mixed-citation id="cns12506-cit-0031" publication-type="journal">
<string-name>
<surname>Gobert</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Joubert</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Curchod</surname>
<given-names>M‐L</given-names>
</string-name>, et al. <article-title>Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits</article-title>. <source xml:lang="en"/>Mol Cell Biol
<year>2009</year>;<volume>29</volume>:<fpage>1538</fpage>–<lpage>1553</lpage>.<pub-id pub-id-type="pmid">19139271</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0032">
<label>32</label>
<mixed-citation id="cns12506-cit-0032" publication-type="journal">
<string-name>
<surname>Gravel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Robert</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kottis</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gallouzi</surname>
<given-names>IE</given-names>
</string-name>, <string-name>
<surname>Pelletier</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>PE</given-names>
</string-name>. <article-title>2′,3′‐Cyclic nucleotide 3′‐phosphodiesterase: A novel RNA‐binding protein that inhibits protein synthesis</article-title>. <source xml:lang="en"/>J Neurosci Res
<year>2009</year>;<volume>87</volume>:<fpage>1069</fpage>–<lpage>1079</lpage>.<pub-id pub-id-type="pmid">19021295</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0033">
<label>33</label>
<mixed-citation id="cns12506-cit-0033" publication-type="journal">
<string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gravel</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Thibault</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Braun</surname>
<given-names>PE</given-names>
</string-name>. <article-title>Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein</article-title>. <source xml:lang="en"/>J Cell Biol
<year>2005</year>;<volume>170</volume>:<fpage>661</fpage>–<lpage>673</lpage>.<pub-id pub-id-type="pmid">16103231</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0034">
<label>34</label>
<mixed-citation id="cns12506-cit-0034" publication-type="journal">
<string-name>
<surname>Croxford</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Pryce</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>
<given-names>SJ</given-names>
</string-name>, et al. <article-title>Cannabinoid‐mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis</article-title>. <source xml:lang="en"/>J Neuroimmunol
<year>2008</year>;<volume>193</volume>:<fpage>120</fpage>–<lpage>129</lpage>.<pub-id pub-id-type="pmid">18037503</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0035">
<label>35</label>
<mixed-citation id="cns12506-cit-0035" publication-type="journal">
<string-name>
<surname>Pryce</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ahmed</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Hankey</surname>
<given-names>DJR</given-names>
</string-name>, et al. <article-title>Cannabinoids inhibit neurodegeneration in models of multiple sclerosis</article-title>. <source xml:lang="en"/>Brain
<year>2003</year>;<volume>126</volume>:<fpage>2191</fpage>–<lpage>2202</lpage>.<pub-id pub-id-type="pmid">12876144</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0036">
<label>36</label>
<mixed-citation id="cns12506-cit-0036" publication-type="journal">
<string-name>
<surname>Cabranes</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Venderova</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>De Lago</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis</article-title>. <source xml:lang="en"/>Neurobiol Dis
<year>2005</year>;<volume>20</volume>:<fpage>207</fpage>–<lpage>217</lpage>.<pub-id pub-id-type="pmid">16242629</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0037">
<label>37</label>
<mixed-citation id="cns12506-cit-0037" publication-type="journal">
<string-name>
<surname>Witting</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cudaback</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Experimental autoimmune encephalomyelitis disrupts endocannabinoid‐mediated neuroprotection</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci USA
<year>2006</year>;<volume>103</volume>:<fpage>6362</fpage>–<lpage>6367</lpage>.<pub-id pub-id-type="pmid">16571660</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0038">
<label>38</label>
<mixed-citation id="cns12506-cit-0038" publication-type="journal">
<string-name>
<surname>Centonze</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Bari</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rossi</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis</article-title>. <source xml:lang="en"/>Brain
<year>2007</year>;<volume>130</volume>:<fpage>2543</fpage>–<lpage>2553</lpage>.<pub-id pub-id-type="pmid">17626034</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0039">
<label>39</label>
<mixed-citation id="cns12506-cit-0039" publication-type="journal">
<string-name>
<surname>Bernal‐Chico</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Canedo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Manterola</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo</article-title>. <source xml:lang="en"/>Glia
<year>2015</year>;<volume>63</volume>:<fpage>163</fpage>–<lpage>176</lpage>.<pub-id pub-id-type="pmid">25130621</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0040">
<label>40</label>
<mixed-citation id="cns12506-cit-0040" publication-type="journal">
<string-name>
<surname>Kreutz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ghadban</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Korf</surname>
<given-names>HW</given-names>
</string-name>, <string-name>
<surname>Dehghani</surname>
<given-names>F</given-names>
</string-name>. <article-title>Cannabinoids and neuronal damage: Differential effects of THC, AEA and 2‐AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures</article-title>. <source xml:lang="en"/>Exp Neurol
<year>2007</year>;<volume>203</volume>:<fpage>246</fpage>–<lpage>257</lpage>.<pub-id pub-id-type="pmid">17010339</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0041">
<label>41</label>
<mixed-citation id="cns12506-cit-0041" publication-type="journal">
<string-name>
<surname>Melis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pillolla</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bisogno</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Protective activation of the endocannabinoid system during ischemia in dopamine neurons</article-title>. <source xml:lang="en"/>Neurobiol Dis
<year>2006</year>;<volume>24</volume>:<fpage>15</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">16762556</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0042">
<label>42</label>
<mixed-citation id="cns12506-cit-0042" publication-type="journal">
<string-name>
<surname>Panikashvili</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mechoulam</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Beni</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Alexandrovich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Shohami</surname>
<given-names>E</given-names>
</string-name>. <article-title>CB1 cannabinoid receptors are involved in neuroprotection via NF‐kappa B inhibition</article-title>. <source xml:lang="en"/>J Cereb Blood Flow Metab
<year>2005</year>;<volume>25</volume>:<fpage>477</fpage>–<lpage>484</lpage>.<pub-id pub-id-type="pmid">15729296</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0043">
<label>43</label>
<mixed-citation id="cns12506-cit-0043" publication-type="journal">
<string-name>
<surname>Mi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>LINGO‐1 negatively regulates myelination by oligodendrocytes</article-title>. <source xml:lang="en"/>Nat Neurosci
<year>2005</year>;<volume>8</volume>:<fpage>745</fpage>–<lpage>751</lpage>.<pub-id pub-id-type="pmid">15895088</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0044">
<label>44</label>
<mixed-citation id="cns12506-cit-0044" publication-type="journal">
<string-name>
<surname>Petratos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Azari</surname>
<given-names>MF</given-names>
</string-name>, <string-name>
<surname>Ozturk</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Papadopoulos</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Bernard</surname>
<given-names>CCA</given-names>
</string-name>. <article-title>Novel therapeutic targets for axonal degeneration in multiple sclerosis</article-title>. <source xml:lang="en"/>J Neuropathol Exp Neurol
<year>2010</year>;<volume>69</volume>:<fpage>323</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">20448478</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0045">
<label>45</label>
<mixed-citation id="cns12506-cit-0045" publication-type="journal">
<string-name>
<surname>Alcamo</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Chirivella</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dautzenberg</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Satb2 regulates callosal projection neuron identity in the developing cerebral cortex</article-title>. <source xml:lang="en"/>Neuron
<year>2008</year>;<volume>57</volume>:<fpage>364</fpage>–<lpage>377</lpage>.<pub-id pub-id-type="pmid">18255030</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0046">
<label>46</label>
<mixed-citation id="cns12506-cit-0046" publication-type="journal">
<string-name>
<surname>Baranek</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dittrich</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Parthasarathy</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Protooncogene Ski cooperates with the chromatin‐remodeling factor Satb2 in specifying callosal neurons</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci
<year>2012</year>; <volume>109</volume>:<fpage>3546</fpage>–<lpage>3551</lpage>.<pub-id pub-id-type="pmid">22334647</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0047">
<label>47</label>
<mixed-citation id="cns12506-cit-0047" publication-type="journal">
<string-name>
<surname>Bartolomucci</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>La Corte</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Possenti</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>TLQP‐21, a VGF‐derived peptide, increases energy expenditure and prevents the early phase of diet‐induced obesity</article-title>. <source xml:lang="en"/>Proc Natl Acad Sci USA
<year>2006</year>;<volume>103</volume>:<fpage>14584</fpage>–<lpage>14589</lpage>.<pub-id pub-id-type="pmid">16983076</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0048">
<label>48</label>
<mixed-citation id="cns12506-cit-0048" publication-type="journal">
<string-name>
<surname>Yamaguchi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Satomi</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Peptidomic identification and biological validation of neuroendocrine regulatory peptide‐1 and ‐2</article-title>. <source xml:lang="en"/>J Biol Chem
<year>2007</year>;<volume>282</volume>:<fpage>26354</fpage>–<lpage>26360</lpage>.<pub-id pub-id-type="pmid">17609209</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0049">
<label>49</label>
<mixed-citation id="cns12506-cit-0049" publication-type="journal">
<string-name>
<surname>Pompl</surname>
<given-names>PN</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bianchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McManus</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Qin</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Pasinetti</surname>
<given-names>GM</given-names>
</string-name>. <article-title>A therapeutic role for cyclooxygenase‐2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis</article-title>. <source xml:lang="en"/>FASEB J
<year>2003</year>;<volume>17</volume>:<fpage>725</fpage>–<lpage>727</lpage>.<pub-id pub-id-type="pmid">12586733</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0050">
<label>50</label>
<mixed-citation id="cns12506-cit-0050" publication-type="journal">
<string-name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Lange</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis</article-title>. <source xml:lang="en"/>Int J Med Sci
<year>2008</year>;<volume>5</volume>:<fpage>92</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">18432310</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0051">
<label>51</label>
<mixed-citation id="cns12506-cit-0051" publication-type="journal">
<string-name>
<surname>Cunnea</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mháille</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>McQuaid</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Farrell</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>FitzGerald</surname>
<given-names>U</given-names>
</string-name>. <article-title>Expression profiles of endoplasmic reticulum stress‐related molecules in demyelinating lesions and multiple sclerosis</article-title>. <source xml:lang="en"/>Mult Scler
<year>2011</year>;<volume>17</volume>:<fpage>808</fpage>–<lpage>818</lpage>.<pub-id pub-id-type="pmid">21382862</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0052">
<label>52</label>
<mixed-citation id="cns12506-cit-0052" publication-type="journal">
<string-name>
<surname>McMahon</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>McQuaid</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>FitzGerald</surname>
<given-names>UF</given-names>
</string-name>. <article-title>Increased expression of ER stress‐ and hypoxia‐associated molecules in grey matter lesions in multiple sclerosis</article-title>. <source xml:lang="en"/>Mult Scler
<year>2012</year>;<volume>18</volume>:<fpage>1437</fpage>–<lpage>1447</lpage>.<pub-id pub-id-type="pmid">22354737</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0053">
<label>53</label>
<mixed-citation id="cns12506-cit-0053" publication-type="journal">
<string-name>
<surname>Ní Fhlathartaigh</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Calreticulin and other components of endoplasmic reticulum stress in rat and human inflammatory demyelination</article-title>. <source xml:lang="en"/>Acta Neuropathol Commun
<year>2013</year>;<volume>1</volume>:<fpage>37</fpage>.<pub-id pub-id-type="pmid">24252779</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0054">
<label>54</label>
<mixed-citation id="cns12506-cit-0054" publication-type="journal">
<string-name>
<surname>Quarles</surname>
<given-names>RH</given-names>
</string-name>. <article-title>Myelin‐associated glycoprotein (MAG): Past, present and beyond</article-title>. <source xml:lang="en"/>J Neurochem
<year>2007</year>;<volume>100</volume>:<fpage>1431</fpage>–<lpage>1448</lpage>.<pub-id pub-id-type="pmid">17241126</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0055">
<label>55</label>
<mixed-citation id="cns12506-cit-0055" publication-type="journal">
<string-name>
<surname>Rowitch</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Kriegstein</surname>
<given-names>AR</given-names>
</string-name>. <article-title>Developmental genetics of vertebrate glial‐cell specification</article-title>. <source xml:lang="en"/>Nature
<year>2010</year>;<volume>468</volume>:<fpage>214</fpage>–<lpage>222</lpage>.<pub-id pub-id-type="pmid">21068830</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0056">
<label>56</label>
<mixed-citation id="cns12506-cit-0056" publication-type="journal">
<string-name>
<surname>Hornig</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fröb</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Vogl</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Hermans‐Borgmeyer</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Tamm</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Wegner</surname>
<given-names>M</given-names>
</string-name>. <article-title>The transcription factors Sox10 and Myrf define an essential regulatory network module in differentiating oligodendrocytes</article-title>. <source xml:lang="en"/>PLoS Genet
<year>2013</year>;<volume>9</volume>:<fpage>e1003907</fpage>.<pub-id pub-id-type="pmid">24204311</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0057">
<label>57</label>
<mixed-citation id="cns12506-cit-0057" publication-type="journal">
<string-name>
<surname>Wegener</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Deboux</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Bachelin</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination</article-title>. <source xml:lang="en"/>Brain
<year>2015</year>;<volume>138</volume>:<fpage>120</fpage>–<lpage>135</lpage>.<pub-id pub-id-type="pmid">25564492</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0058">
<label>58</label>
<mixed-citation id="cns12506-cit-0058" publication-type="journal">
<string-name>
<surname>Franco‐Pons</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Virgos</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vogel</surname>
<given-names>WF</given-names>
</string-name>, et al. <article-title>Expression of discoidin domain receptor 1 during mouse brain development follows the progress of myelination</article-title>. <source xml:lang="en"/>Neuroscience
<year>2006</year>;<volume>140</volume>:<fpage>463</fpage>–<lpage>475</lpage>.<pub-id pub-id-type="pmid">16603319</pub-id></mixed-citation>
</ref>
<ref id="cns12506-bib-0059">
<label>59</label>
<mixed-citation id="cns12506-cit-0059" publication-type="journal">
<string-name>
<surname>Ghiani</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Starcevic</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rodriguez‐Fernandez</surname>
<given-names>IA</given-names>
</string-name>, et al. <article-title>The dysbindin‐containing complex (BLOC‐1) in brain: Developmental regulation, interaction with SNARE proteins and role in neurite outgrowth</article-title>. <source xml:lang="en"/>Mol Psychiatry
<year>2010</year>;<volume>15</volume>:<fpage>204</fpage>–<lpage>215</lpage>.</mixed-citation>
</ref>
<ref id="cns12506-bib-0060">
<label>60</label>
<mixed-citation id="cns12506-cit-0060" publication-type="journal">
<string-name>
<surname>Kubota</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kumamoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Matsuzaki</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Dysbindin engages in c‐Jun N‐terminal kinase activity and cytoskeletal organization</article-title>. <source xml:lang="en"/>Biochem Biophys Res Commun
<year>2009</year>;<volume>379</volume>:<fpage>191</fpage>–<lpage>195</lpage>.<pub-id pub-id-type="pmid">19094965</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>